[Form 4] Graco Inc Insider Trading Activity
Inozyme Pharma, Inc. (INZY) filed Post-Effective Amendment No. 1 to its two shelf registration statements (Nos. 333-258702 and 333-275364) to deregister all remaining unsold securities, which had allowed for the issuance of up to $500 million of common stock, preferred stock, debt securities and related instruments. The amendment follows the closing of the previously announced merger completed on July 1, 2025, in which Incline Merger Sub, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., merged with and into Inozyme, leaving Inozyme as a wholly-owned subsidiary of BioMarin. Because the merger terminates any independent public offering activity, the company is withdrawing the shelves and terminating their effectiveness.
Inozyme Pharma, Inc. (INZY) ha presentato l'Emendamento Post-Esecutivo n. 1 alle sue due dichiarazioni di registrazione a scaffale (n. 333-258702 e 333-275364) per cancellare la registrazione di tutti i titoli invenduti rimanenti, che consentivano l'emissione fino a 500 milioni di dollari di azioni ordinarie, azioni privilegiate, titoli di debito e strumenti correlati. L'emendamento segue la chiusura della fusione precedentemente annunciata, completata il 1 luglio 2025, in cui Incline Merger Sub, Inc., una controllata interamente posseduta da BioMarin Pharmaceutical Inc., si 猫 fusa con Inozyme, lasciando Inozyme come controllata interamente posseduta da BioMarin. Poich茅 la fusione pone fine a qualsiasi attivit脿 indipendente di offerta pubblica, la societ脿 sta ritirando le registrazioni a scaffale e ne sta terminando l'efficacia.
Inozyme Pharma, Inc. (INZY) present贸 la Enmienda Post-Efectiva No. 1 a sus dos declaraciones de registro en estanter铆a (Nros. 333-258702 y 333-275364) para cancelar la inscripci贸n de todos los valores no vendidos restantes, que permit铆an la emisi贸n de hasta 500 millones de d贸lares en acciones ordinarias, acciones preferentes, valores de deuda e instrumentos relacionados. La enmienda sigue al cierre de la fusi贸n previamente anunciada, completada el 1 de julio de 2025, en la que Incline Merger Sub, Inc., una subsidiaria de propiedad total de BioMarin Pharmaceutical Inc., se fusion贸 con Inozyme, dejando a Inozyme como subsidiaria de propiedad total de BioMarin. Debido a que la fusi贸n termina cualquier actividad independiente de oferta p煤blica, la compa帽铆a est谩 retirando las declaraciones en estanter铆a y terminando su vigencia.
Inozyme Pharma, Inc. (INZY)電� 霊� 臧滌潣 靹犽皹 霌彪 氇呾劯靹�(氩堩樃 333-258702 氚� 333-275364)鞐� 雽�頃� 靷泟 須牓 靾橃爼鞎� 1順鸽ゼ 鞝滌稖頃橃棳 雮晞鞛堧姅 氙疙寪毵� 歃濌秾 鞝勲秬鞚� 霌彪鞚� 毵愳唽頃橃榾鞀惦媹雼�. 鞚� 氇呾劯靹滊姅 氤错喌欤�, 鞖办劆欤�, 毂勲 歃濌秾 氚� 甏�霠� 旮堨湹靸來拡鞙茧 斓滊寑 5鞏� 雼煬旯岇 氚滍枆頃� 靾� 鞛堧弰搿� 項堨毄頄堨姷雼堧嫟. 鞚� 靾橃爼鞎堨潃 2025雲� 7鞗� 1鞚�鞐� 鞕勲霅� 鞚挫爠鞐� 氚滍憸霅� 頃╇硲鞚� 毵堦皭鞐� 霐半ジ 瓴冹溂搿�, BioMarin Pharmaceutical Inc.鞚� 鞝勳暋 於滌瀽 鞛愴殞靷澑 Incline Merger Sub, Inc.臧� Inozyme鞕� 頃╇硲頃橃棳 Inozyme臧� BioMarin鞚� 鞝勳暋 於滌瀽 鞛愴殞靷皜 霅橃棃鞀惦媹雼�. 頃╇硲鞙茧 鞚疙暣 霃呺鞝侅澑 瓿店皽 氚滍枆 頇滊彊鞚� 膦呺霅橂瘈搿� 須岇偓電� 靹犽皹 霌彪鞚� 觳犿殞頃橁碃 攴� 須牓鞚� 膦呺頃╇媹雼�.
Inozyme Pharma, Inc. (INZY) a d茅pos茅 l'Amendement Post-Efficace n掳 1 脿 ses deux d茅clarations d'enregistrement sur 茅tag猫re (n掳 333-258702 et 333-275364) afin de radier tous les titres invendus restants, qui permettaient l'茅mission jusqu'脿 500 millions de dollars d'actions ordinaires, d'actions privil茅gi茅es, de titres de dette et d'instruments associ茅s. Cet amendement fait suite 脿 la cl么ture de la fusion pr茅c茅demment annonc茅e, finalis茅e le 1er juillet 2025, au cours de laquelle Incline Merger Sub, Inc., une filiale en propri茅t茅 exclusive de BioMarin Pharmaceutical Inc., a fusionn茅 avec Inozyme, faisant d'Inozyme une filiale en propri茅t茅 exclusive de BioMarin. 脡tant donn茅 que la fusion met fin 脿 toute activit茅 ind茅pendante d'offre publique, la soci茅t茅 retire les registres sur 茅tag猫re et met fin 脿 leur validit茅.
Inozyme Pharma, Inc. (INZY) hat den Post-Effective Amendment Nr. 1 zu seinen beiden Shelf-Registrierungsunterlagen (Nr. 333-258702 und 333-275364) eingereicht, um alle verbleibenden unverkauften Wertpapiere zu deregistrieren, die die Ausgabe von bis zu 500 Millionen US-Dollar an Stammaktien, Vorzugsaktien, Schuldverschreibungen und verwandten Instrumenten erm枚glichten. Die 脛nderung folgt dem Abschluss der zuvor angek眉ndigten Fusion, die am 1. Juli 2025 abgeschlossen wurde, bei der Incline Merger Sub, Inc., eine hundertprozentige Tochtergesellschaft von BioMarin Pharmaceutical Inc., mit Inozyme verschmolzen wurde, wodurch Inozyme eine hundertprozentige Tochtergesellschaft von BioMarin wurde. Da die Fusion jegliche unabh盲ngige 枚ffentliche Angebotst盲tigkeit beendet, zieht das Unternehmen die Shelf-Registrierungen zur眉ck und beendet deren Wirksamkeit.
- Merger with BioMarin closed on July 1, 2025, making Inozyme a wholly-owned subsidiary.
- Withdrawal of unsold securities eliminates future dilution and associated filing obligations.
- No future independent capital-raising capacity for Inozyme as a standalone public entity.
- All securities previously available under $500 million shelves are now unrecoverable for public investors.
Insights
TL;DR: Housekeeping filing withdraws $500 m shelves after BioMarin takeover; limited standalone market impact.
The amendment formally removes unsold securities from two Form S-3 shelves, confirming that Inozyme will no longer raise capital as an independent issuer following its acquisition by BioMarin. From a securities-law perspective, the step is required to avoid lingering registration obligations and filing fees. Investors already anticipated delisting at closing, so the impact on valuation or liquidity is negligible. Rating reflects procedural, not financial, significance.
TL;DR: Deregistration signals official close of BioMarin鈥揑nozyme merger; integration phase begins.
This filing confirms consummation of the May 16, 2025 Merger Agreement. By terminating the shelves, Inozyme finalizes legal clean-up and ceases to exist as a separate SEC registrant. While important for regulatory completeness, it carries no new economic terms beyond the previously disclosed merger. The action is standard in post-closing practice and does not alter the transaction鈥檚 strategic or financial rationale.
Inozyme Pharma, Inc. (INZY) ha presentato l'Emendamento Post-Esecutivo n. 1 alle sue due dichiarazioni di registrazione a scaffale (n. 333-258702 e 333-275364) per cancellare la registrazione di tutti i titoli invenduti rimanenti, che consentivano l'emissione fino a 500 milioni di dollari di azioni ordinarie, azioni privilegiate, titoli di debito e strumenti correlati. L'emendamento segue la chiusura della fusione precedentemente annunciata, completata il 1 luglio 2025, in cui Incline Merger Sub, Inc., una controllata interamente posseduta da BioMarin Pharmaceutical Inc., si 猫 fusa con Inozyme, lasciando Inozyme come controllata interamente posseduta da BioMarin. Poich茅 la fusione pone fine a qualsiasi attivit脿 indipendente di offerta pubblica, la societ脿 sta ritirando le registrazioni a scaffale e ne sta terminando l'efficacia.
Inozyme Pharma, Inc. (INZY) present贸 la Enmienda Post-Efectiva No. 1 a sus dos declaraciones de registro en estanter铆a (Nros. 333-258702 y 333-275364) para cancelar la inscripci贸n de todos los valores no vendidos restantes, que permit铆an la emisi贸n de hasta 500 millones de d贸lares en acciones ordinarias, acciones preferentes, valores de deuda e instrumentos relacionados. La enmienda sigue al cierre de la fusi贸n previamente anunciada, completada el 1 de julio de 2025, en la que Incline Merger Sub, Inc., una subsidiaria de propiedad total de BioMarin Pharmaceutical Inc., se fusion贸 con Inozyme, dejando a Inozyme como subsidiaria de propiedad total de BioMarin. Debido a que la fusi贸n termina cualquier actividad independiente de oferta p煤blica, la compa帽铆a est谩 retirando las declaraciones en estanter铆a y terminando su vigencia.
Inozyme Pharma, Inc. (INZY)電� 霊� 臧滌潣 靹犽皹 霌彪 氇呾劯靹�(氩堩樃 333-258702 氚� 333-275364)鞐� 雽�頃� 靷泟 須牓 靾橃爼鞎� 1順鸽ゼ 鞝滌稖頃橃棳 雮晞鞛堧姅 氙疙寪毵� 歃濌秾 鞝勲秬鞚� 霌彪鞚� 毵愳唽頃橃榾鞀惦媹雼�. 鞚� 氇呾劯靹滊姅 氤错喌欤�, 鞖办劆欤�, 毂勲 歃濌秾 氚� 甏�霠� 旮堨湹靸來拡鞙茧 斓滊寑 5鞏� 雼煬旯岇 氚滍枆頃� 靾� 鞛堧弰搿� 項堨毄頄堨姷雼堧嫟. 鞚� 靾橃爼鞎堨潃 2025雲� 7鞗� 1鞚�鞐� 鞕勲霅� 鞚挫爠鞐� 氚滍憸霅� 頃╇硲鞚� 毵堦皭鞐� 霐半ジ 瓴冹溂搿�, BioMarin Pharmaceutical Inc.鞚� 鞝勳暋 於滌瀽 鞛愴殞靷澑 Incline Merger Sub, Inc.臧� Inozyme鞕� 頃╇硲頃橃棳 Inozyme臧� BioMarin鞚� 鞝勳暋 於滌瀽 鞛愴殞靷皜 霅橃棃鞀惦媹雼�. 頃╇硲鞙茧 鞚疙暣 霃呺鞝侅澑 瓿店皽 氚滍枆 頇滊彊鞚� 膦呺霅橂瘈搿� 須岇偓電� 靹犽皹 霌彪鞚� 觳犿殞頃橁碃 攴� 須牓鞚� 膦呺頃╇媹雼�.
Inozyme Pharma, Inc. (INZY) a d茅pos茅 l'Amendement Post-Efficace n掳 1 脿 ses deux d茅clarations d'enregistrement sur 茅tag猫re (n掳 333-258702 et 333-275364) afin de radier tous les titres invendus restants, qui permettaient l'茅mission jusqu'脿 500 millions de dollars d'actions ordinaires, d'actions privil茅gi茅es, de titres de dette et d'instruments associ茅s. Cet amendement fait suite 脿 la cl么ture de la fusion pr茅c茅demment annonc茅e, finalis茅e le 1er juillet 2025, au cours de laquelle Incline Merger Sub, Inc., une filiale en propri茅t茅 exclusive de BioMarin Pharmaceutical Inc., a fusionn茅 avec Inozyme, faisant d'Inozyme une filiale en propri茅t茅 exclusive de BioMarin. 脡tant donn茅 que la fusion met fin 脿 toute activit茅 ind茅pendante d'offre publique, la soci茅t茅 retire les registres sur 茅tag猫re et met fin 脿 leur validit茅.
Inozyme Pharma, Inc. (INZY) hat den Post-Effective Amendment Nr. 1 zu seinen beiden Shelf-Registrierungsunterlagen (Nr. 333-258702 und 333-275364) eingereicht, um alle verbleibenden unverkauften Wertpapiere zu deregistrieren, die die Ausgabe von bis zu 500 Millionen US-Dollar an Stammaktien, Vorzugsaktien, Schuldverschreibungen und verwandten Instrumenten erm枚glichten. Die 脛nderung folgt dem Abschluss der zuvor angek眉ndigten Fusion, die am 1. Juli 2025 abgeschlossen wurde, bei der Incline Merger Sub, Inc., eine hundertprozentige Tochtergesellschaft von BioMarin Pharmaceutical Inc., mit Inozyme verschmolzen wurde, wodurch Inozyme eine hundertprozentige Tochtergesellschaft von BioMarin wurde. Da die Fusion jegliche unabh盲ngige 枚ffentliche Angebotst盲tigkeit beendet, zieht das Unternehmen die Shelf-Registrierungen zur眉ck und beendet deren Wirksamkeit.
FAQ
Why did Inozyme Pharma (INZY) file a POS AM on July 1, 2025?
How much in securities are being deregistered by INZY?
Which registration statements are affected?
What event triggered the deregistration of Inozyme鈥檚 shelves?
Is Inozyme still an independent public company after July 1, 2025?
